Trial Profile
A phase 2 study of O-benzylguanine (O-BG) and temozolomide in patients with glioblastoma progressing at least 3 months after completion of primary treatment with radiation therapy and temozolomide.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 07 Feb 2017 Status changed from completed to discontinued.
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 27 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.